Please use this identifier to cite or link to this item: https://doi.org/10.1177/0269881113480990
Title: Full central neurokinin-1 receptor blockade is required for efficacy in depression: Evidence from orvepitant clinical studies
Authors: Ratti, E.
Bettica, P.
Alexander, R.
Archer, G.
Carpenter, D.
Evoniuk, G.
Gomeni, R.
Lawson, E.
Lopez, M.
Millns, H.
Rabiner, E.A.
Trist, D.
Trower, M.
Zamuner, S.
Krishnan, R. 
Fava, M.
Keywords: clinical trials
Depression
neurokinin
receptor occupancy
substance P
Issue Date: May-2013
Citation: Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., Rabiner, E.A., Trist, D., Trower, M., Zamuner, S., Krishnan, R., Fava, M. (2013-05). Full central neurokinin-1 receptor blockade is required for efficacy in depression: Evidence from orvepitant clinical studies. Journal of Psychopharmacology 27 (5) : 424-434. ScholarBank@NUS Repository. https://doi.org/10.1177/0269881113480990
Abstract: Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [11C]GR205171 binding indicated that oral orvepitant doses of 30-60 mg/day provided >99% receptor occupancy for ≥24 h. Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)≥22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1:1:1). Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures. Study 733 (n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: -2.41, 95% confidence interval (CI) (-4.50 to -0.31) p=0.0245; 60 mg: -2.86, 95% CI (-4.97 to -0.75) p=0.0082). Study 833 (n=345) did not show significance (estimated drug-placebo differences of 30 mg: -1.67, 95% CI (-3.73 to 0.39) p=0.1122; 60 mg: -0.76, 95% CI (-2.85 to 1.32) p=0.4713). The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD. © The Author(s) 2013.
Source Title: Journal of Psychopharmacology
URI: http://scholarbank.nus.edu.sg/handle/10635/110538
ISSN: 02698811
DOI: 10.1177/0269881113480990
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

23
checked on Sep 21, 2018

WEB OF SCIENCETM
Citations

25
checked on Sep 11, 2018

Page view(s)

28
checked on Aug 10, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.